Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

Leukemia

Volumn 28, Issue 2, 2014, Pages 329-337

  Sakamaki, I ^a   Kwak, L W ^a   Cha, S C ^a   Yi, Q ^a   Lerman, B ^a   Chen, J ^b   Surapaneni, S ^b   Bateman, S ^b   Qin, H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

adjuvant; DNA vaccine; lenalidomide; lymphoma; T cell

Indexed keywords

CYCLOPHOSPHAMIDE; DNA LYMPHOMA VACCINE; DNA VACCINE; LENALIDOMIDE; LYMPHOMA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T CELL DEPLETION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; VACCINATION;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; LYMPHOMA; MICE; T-LYMPHOCYTE SUBSETS; THALIDOMIDE; TUMOR BURDEN;

EID: 84893769637     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.177     Document Type: Article

References (36)

1. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent nonhodgkin's lymphoma. J Clin Oncol 2009; 27: 5404-5409.
2. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
3. Fowler N, McLaughlin P, Hagemeister FB, Kwak LW, Fanale M, Neelapu S et al. A Biologic combination of lenalidomide and rituximab for front-line therapy of indolent b-cell non-hodgkin's lymphoma. Blood 2009; 114: abstract 1714.
4. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011; 25: 1877-1881.
5. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34\+ progenitor cells. Cancer Res 2007; 67: 746-755.
6. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
7. Xu YB, Li JW, Ferguson GD, Mercurio F, Khambatta G, Morrison L et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009; 114: 338-345.
8. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H. et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336.
9. Li SR, Pal R, Monaghan SA, Schafer P, Ouyang HJ, Mapara M et al. IMiD immunomodulatory compounds block C/EBP beta translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011; 117: 5157-5165.
10. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166-1172.
11. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM et al. S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002; 62: 2300-2305.
12. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
13. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor-necrosis-factor-alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
14. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
15. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116: 3227-3237.
16. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103: 1787-1790.
17. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62: 39-49.
18. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
19. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17: 3520-3526.
20. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-2127.
21. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29: 2787-2794.
22. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
23. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-258.
24. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, Baskar S et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004; 104: 1961-1969.
25. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167: 6644-6653.
26. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 2009; 114: 4142-4149.
27. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002; 168: 3983-3991.
28. Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol 2010; 92: 118-126.
29. Qin H, Cha SC, Neelapu SS, Liu C, Wang YH, Wei J et al. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine 2010; 28: 7970-7978.
30. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-4332.
31. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168: 4914-4919.
32. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
33. Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012; 18: 1426-1434.
34. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
35. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008; 57: 1849-1859.
36. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.